Amyotrophic Lateral Sclerosis
Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond
Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology
Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects
SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay
Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models
Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models
Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research
ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development
Denali Therapeutics Faces Another Setback in ALS Treatment Development
Denali Therapeutics, ALS, Phase II/III trial, HEALEY ALS Platform trial, DNL343, treatment failure
Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies
Eli Lilly, Alchemab Therapeutics, ALS, Therapeutic Antibodies, Neurodegenerative Disease, Drug Development
Denali Therapeutics’ ALS Drug DNL343 Fails to Meet Primary Efficacy Endpoints in Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics, DNL343, ALS (Amyotrophic Lateral Sclerosis), HEALEY ALS Platform Trial, eIF2B agonist, Clinical trial failure, Neurodegenerative diseases
Corcept’s ALS Drug Trial Misses Primary Endpoint, Yet Shows Promising Survival Benefit
Corcept Therapeutics, Dazucorilant, ALS (Amyotrophic Lateral Sclerosis), Phase 2 trial, Survival benefit, Fast Track Designation, Cortisol modulator
Mitsubishi Tanabe and Dewpoint Therapeutics Collaborate on $480M ALS Treatment Development
ALS treatment, Dewpoint Therapeutics, Mitsubishi Tanabe Pharma Corporation, TDP-43, small molecule condensate modulator, biobucks deal
PTC Therapeutics Sells Priority Review Voucher for $150M Following Phase 2 ALS Trial Failure
PTC Therapeutics, ALS, Phase 2 trial failure, priority review voucher, $150M sale